2025 China Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 China Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in China are WuXi Biologics, Asymchem, Hansoh, and Shanghai Pharma Industrial. WuXi Biologics is a global leader with flexible large-scale antibody manufacturing capacity exceeding 30,000 liters, specializing in antibody-drug conjugates and advanced cell lines, serving clients worldwide. Asymchem offers end-to-end antibody production services, recognized for innovative antibody engineering and sustainable manufacturing practices, primarily within China. Hansoh focuses on therapeutic antibodies and biosimilars with cost-efficient manufacturing tailored to Asian and growing international markets. Shanghai Pharma Industrial delivers custom antibody development with significant large-scale production capacity, serving mainly Asia-Pacific and expanding globally.
These companies are pivotal to China’s rapidly expanding biosimilar contract manufacturing sector, which benefits from cost-effective production and a rising domestic biosimilar pipeline. China’s biosimilar market was valued at $1.54 billion in 2022 and is growing at an estimated CAGR of 23.7% through 2030, fueled by strong regulatory support and increasing biosimilar approvals. The Chinese industry is bolstered by strategic investments, such as joint ventures and facility expansions, exemplified by AutekBio’s planned $100 million biologics R&D and manufacturing center in Beijing aiming to become Asia’s largest CMO facility. This growth is supported by increasing demand for biologics driven by shifts in disease burden and reimbursement pressures favorable to biosimilars.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in China are WuXi Biologics, Asymchem, Hansoh, and Shanghai Pharma Industrial. WuXi Biologics is a global leader with flexible large-scale antibody manufacturing capacity exceeding 30,000 liters, specializing in antibody-drug conjugates and advanced cell lines, serving clients worldwide. Asymchem offers end-to-end antibody production services, recognized for innovative antibody engineering and sustainable manufacturing practices, primarily within China. Hansoh focuses on therapeutic antibodies and biosimilars with cost-efficient manufacturing tailored to Asian and growing international markets. Shanghai Pharma Industrial delivers custom antibody development with significant large-scale production capacity, serving mainly Asia-Pacific and expanding globally.
These companies are pivotal to China’s rapidly expanding biosimilar contract manufacturing sector, which benefits from cost-effective production and a rising domestic biosimilar pipeline. China’s biosimilar market was valued at $1.54 billion in 2022 and is growing at an estimated CAGR of 23.7% through 2030, fueled by strong regulatory support and increasing biosimilar approvals. The Chinese industry is bolstered by strategic investments, such as joint ventures and facility expansions, exemplified by AutekBio’s planned $100 million biologics R&D and manufacturing center in Beijing aiming to become Asia’s largest CMO facility. This growth is supported by increasing demand for biologics driven by shifts in disease burden and reimbursement pressures favorable to biosimilars.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
